La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

RaySearch Laboratories Gestione

Gestione criteri di controllo 3/4

RaySearch Laboratories' Il CEO è Johan Lof, nominato in Jan2000, e ha un mandato di 24.58 anni. la retribuzione annua totale è SEK 9.76M, composta da 66.2% di stipendio e 33.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 16.51% delle azioni della società, per un valore di € 74.86M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.8 anni e 20.9 anni.

Informazioni chiave

Johan Lof

Amministratore delegato

SEK 9.8m

Compenso totale

Percentuale dello stipendio del CEO	66.2%
Mandato del CEO	24.7yrs
Proprietà del CEO	16.5%
Durata media del management	5.9yrs
Durata media del Consiglio di amministrazione	21yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Johan Lof rispetto agli utili di RaySearch Laboratories?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	SEK 151m
Mar 31 2024	n/a	n/a	SEK 101m
Dec 31 2023	SEK 10m	SEK 6m	SEK 82m
Sep 30 2023	n/a	n/a	SEK 64m
Jun 30 2023	n/a	n/a	SEK 53m
Mar 31 2023	n/a	n/a	SEK 22m
Dec 31 2022	SEK 7m	SEK 6m	SEK 24m
Sep 30 2022	n/a	n/a	-SEK 6m
Jun 30 2022	n/a	n/a	-SEK 38m
Mar 31 2022	n/a	n/a	-SEK 35m
Dec 31 2021	SEK 7m	SEK 6m	-SEK 47m
Sep 30 2021	n/a	n/a	-SEK 46m
Jun 30 2021	n/a	n/a	-SEK 50m
Mar 31 2021	n/a	n/a	-SEK 42m
Dec 31 2020	SEK 7m	SEK 6m	-SEK 9m
Sep 30 2020	n/a	n/a	SEK 24m
Jun 30 2020	n/a	n/a	SEK 43m
Mar 31 2020	n/a	n/a	SEK 74m
Dec 31 2019	SEK 8m	SEK 6m	SEK 50m
Sep 30 2019	n/a	n/a	SEK 64m
Jun 30 2019	n/a	n/a	SEK 85m
Mar 31 2019	n/a	n/a	SEK 84m
Dec 31 2018	SEK 8m	SEK 5m	SEK 79m
Sep 30 2018	n/a	n/a	SEK 118m
Jun 30 2018	n/a	n/a	SEK 104m
Mar 31 2018	n/a	n/a	SEK 103m
Dec 31 2017	SEK 9m	SEK 5m	SEK 118m

Compensazione vs Mercato: La retribuzione totale di Johan ($USD 945.93K ) è circa la media per le aziende di dimensioni simili nel mercato German ($USD 1.10M ).

Compensazione vs guadagni: La retribuzione di Johan è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Johan Lof (55 yo)

24.7yrs

Mandato

SEK 9,758,000

Compensazione

Dr. Johan Lof has been the Chief Executive Officer and President of Raysearch Laboratories AB (Publ) since 2000. Dr. Lof serves as the Chief Executive Officer of RaySearch Medical AB. Dr. Lof has been a Di...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Johan Lof	Founder	24.7yrs	SEK 9.76m	16.51% SEK 76.7m
Bjorn Hardemark	Deputy Chief Executive Officer	9yrs	SEK 3.54m	0.018% SEK 81.3k
Annika Henriksson	Acting Chief Financial Officer	1.2yrs	Nessun dato	Nessun dato
Kjell Eriksson	Head of Research & Chief Science Officer	9yrs	Nessun dato	0.047% SEK 216.7k
Petra Jansson	General Counsel	7.2yrs	Nessun dato	Nessun dato
Peter Kemlin	Director of Sales & Marketing	no data	Nessun dato	0.0041% SEK 18.9k
Tove Alteborg	Global Human Resource Manager	1.2yrs	Nessun dato	Nessun dato
Fredrik Lofman	Head of Machine Learning	4.7yrs	Nessun dato	0.0041% SEK 18.9k
Marc Mlyn	President & CEO of RaySearch Americas	2.7yrs	Nessun dato	Nessun dato

5.9yrs

Durata media

50.5yo

Età media

Gestione esperta: Il team dirigenziale di 27R è esperto e expertise (durata media dell'incarico 5.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Johan Lof	Founder	24.7yrs	SEK 9.76m	16.51% SEK 76.7m
Hans Wigzell	Independent Chairman of Board	20.3yrs	SEK 840.00k	Nessun dato
Carl Bergendal	Independent Director	24.7yrs	SEK 225.00k	3.39% SEK 15.7m
Radhe Mohan	Member of Scientific Advisory Board	21.7yrs	Nessun dato	Nessun dato
Anders Forsgren	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Anders Brahme	Member of Scientific Advisory Board	no data	Nessun dato	3.79% SEK 17.6m
David Jaffray	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Britta Wallgren	Independent Director	6.3yrs	SEK 300.00k	0.020% SEK 94.8k
Gunther Marder	Independent Director	1.8yrs	SEK 300.00k	0.20% SEK 947.6k

21.0yrs

Durata media

70yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 27R è composto da personale esperto e esperto (durata media dell'incarico 20.9 anni).

RaySearch Laboratories Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Deputy Chief Executive Officer recently sold €165k worth of stock

Henrik Bergentoft Leaves the Position as CFO for Raysearch

Founder recently sold €3.4m worth of stock

Founder recently sold €94k worth of stock

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Recent updates

Deputy Chief Executive Officer recently sold €165k worth of stock

RaySearch Laboratories AB (publ) to Report Q1, 2025 Results on May 09, 2025

Second quarter 2024 earnings released: EPS: kr1.79 (vs kr0.32 in 2Q 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 20%

RaySearch to Present the Latest Advances in RayStation , RayCare and RayIntelligence At AAPM 2024

RaySearch Releases RayStation 2024B

RaySearch Laboratories AB (publ) Releases RayCare 2024A

Now 22% undervalued

Raysearch Laboratories AB (Publ) Apprves Ordinary Dividend for the Year 2023

First quarter 2024 earnings released: EPS: kr1.07 (vs kr0.51 in 1Q 2023)

Raysearch to Present the Latest Advances in Raystation, Raycare and Rayintelligence At Estro 2024

Full year 2023 earnings released: EPS: kr2.38 (vs kr0.69 in FY 2022)

New major risk - Revenue and earnings growth

RaySearch Laboratories AB (publ) Proposes an Extra Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024

RaySearch Laboratories AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025

RaySearch Laboratories AB (publ) Releases Raystation 2024A

Third quarter 2023 earnings released: EPS: kr0.63 (vs kr0.29 in 3Q 2022)

RaySearch Laboratories AB (publ) to Report Q2, 2024 Results on Aug 16, 2024

RaySearch to Showcase Latest Innovations in Raystation, RayCare and RayIntelligence to Be Presented at ASTRO 2023

RaySearch Laboratories AB (Publ) to Showcase the Latest Software Innovations At Astro in San Diego, California, October 1-4

RaySearch Laboratories AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Investor sentiment improves as stock rises 16%

Second quarter 2023 earnings released: EPS: kr0.32 (vs kr0.58 loss in 2Q 2022)

RaySearch Laboratories AB (publ) to Report Q1, 2024 Results on May 17, 2024

RaySearch to Present the Latest Advances in Raystation, RayCare and RayIntelligence at AAPM 2023

RaySearch Laboratories AB (Publ) Announces the Release of the Latest Version of RayCare®, the Next Generation Oncology Information System

New minor risk - Share price stability

RaySearch Laboratories AB (publ) Releases Raystation 2023B

Raysearch Laboratories AB (Publ)'s RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

Henrik Bergentoft Leaves the Position as CFO for Raysearch

New minor risk - Insider selling

Founder recently sold €3.4m worth of stock

New minor risk - Shareholder dilution

RaySearch Laboratories AB (publ) Announce to Exhibit Latest Software Innovations for Particle Therapy and BNCT at PTCOG 2023

First quarter 2023 earnings released

Founder recently sold €94k worth of stock

Full year 2022 earnings released: EPS: kr0.69 (vs kr1.38 loss in FY 2021)

RaySearch Laboratories AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

RaySearch Laboratories AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

Third quarter 2022 earnings released

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Second quarter 2022 earnings released

Raysearch Laboratories AB (Publ) Appoints Henrik Bergentoft as Cfo, Effective from November 15, 2022

RaySearch Laboratories AB (publ) Launches RayStation 12A

RaySearch to Exhibit the Latest Software Innovations for Particle Therapy at PTCOG 2022

RaySearch Laboratories AB (publ) Releases Latest Version of RayCare

Founder recently sold €1.9m worth of stock

First quarter 2022 earnings released

Raysearch Laboratories AB (Publ) Announces Raystation, Rayintelligence and Raycare to Be Presented At Estro 2022

Insufficient new directors

RaySearch Laboratories AB (publ) Announces Executive Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Founder recently sold €550k worth of stock

RaySearch AB (publ) Provides Cancer Clinics with User Configurable Workflows for Radiation Therapy

RayStation 11B Brings New Features for Adaptive Workflows, Brachytherapy, and Radiation Therapy with Ions

Third quarter 2021 earnings released

RaySearch Laboratories AB (publ) to Showcase Latest Innovations, RayIntelligence and RayCare at ESTRO 2021

Second quarter 2021 earnings released

Insufficient new directors

RaySearch Laboratories AB (Publ) Announces RayStation 9 Granted Regulatory Clearance in China

Raysearch Announces the Release of A New Version of Raycare®, the Next-Generation Oncology Information System

Raysearch Laboratories Announces the Release of Raystation® 11A

Raysearch Laboratories AB (Publ) Provides Earnings Guidance for 2021

RaySearch Laboratories AB (publ) Announces Royal Brisbane and Women's Hospital Treats First Patients Using the Raystation® Treatment Planning System

Full year 2020 earnings released: kr0.26 loss per share (vs kr1.47 profit in FY 2019)

Revenue misses expectations

RaySearch Laboratories AB (publ) to Report First Half, 2021 Results on Aug 25, 2021